Idis Named Patient Programme Phased Launch

Partnering with Idis to develop an Idis Named Patient Programme Phased Launch will:

• Enable the development of inspired solutions to optimise your brand's launch across global markets
• Help pharmaceutical and biotech companies meet global requests for access to pre-launch brands
• Allow you to benefit from our strategic consultancy to assess markets as viable options for your brand
• Provide you with consolidated information which can be used to mitigate future risks

Once a drug has been launched in one country, enquiries and requests for access often flood in from others.

Using an Idis Named Patient Programme Phased Launch, we can help you manage requests for your brand in countries where it has not yet been launched, where it may never be launched and in markets where its marketing authorisation has lapsed.

Our Idis Named Patient Programme Phased Launch will help you manage any risks associated with running global phased launch programmes, while showing you how to apply the programme to different patients across the world.

As market leaders in our field we're highly experienced in managing programmes for a diverse range of drugs in many different therapeutic areas. In particular, we have extensive knowledge in the area of oncology. In fact, no other company has launched more oncology products than Idis.

By consulting with Idis, you can rest assured that whatever your needs and whatever your therapeutic area, we will have a solution to suit you.

Idis Named Patient Programmes are regulatory compliant in all countries. We have the consultancy expertise to design and create even the most complex programmes and we take care of every regulatory detail, ensuring peace of mind.

We also provide expert advice in countries where the regulatory infrastructure is less well defined.